Multi-therapeutic strategy targeting parasite and inflammation-related alterations to improve prognosis of chronic Chagas cardiomyopathy: a hypothesis-based approach

Joseli Lannes-Vieira

Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Biologia das Interações, Rio de Janeiro, RJ, Brasil

Chagas disease (CD), caused by infection by the protozoan parasite *Trypanosoma cruzi*, presents as main clinical manifestation the chronic chagasic cardiomyopathy (CCC). CCC afflicts millions of people, mostly in Latin America, and vaccine and effective therapy are still lacking. Comprehension of the host/parasite interplay in the chronic phase of *T. cruzi* infection may unveil targets for rational trait-based therapies to improve CCC prognosis. In the present viewpoint, I critically summarise a collection of data, obtained by our network of collaborators and other groups on CCC and preclinical studies on pathogenesis, targeting identification for intervention and the use of drugs with immunomodulatory properties to improve CCC. In the last two decades, models combining mouse lineages and *T. cruzi* strains allowed replication of crucial clinical, histopathological, and immunological traits of CCC. This condition includes conduction changes (heart rate changes, arrhythmias, atrioventricular blocks, prolongation of the QRS complex and PR and corrected QT intervals), ventricular dysfunction and heart failure, CD8-enriched myocarditis, tissue remodeling and progressive fibrosis, and systemic inflammatory profile, resembling “cytokine storm”. Studies on Chagas’ heart disease pathogenesis begins to unveil the molecular mechanisms underpinning the inflammation-related cardiac tissue damage, placing IFNγ, TNF and NFκB signaling as upstream regulators of miRNAs and mRNAs associated with critical biological pathways as cell migration, inflammation, tissue remodeling and fibrosis, and mitochondrial dysfunction. Further, data on preclinical trials using hypothesis-based tools, targeting parasite and inflammation-related alterations, opened paths for multi-therapeutic approaches in CCC. Despite the long path taken using experimental CD models replicating relevant aspects of CCC and testing new therapies and therapeutic schemes, these findings may get lost in translation, as conceptual and economical challenges, underpinning the valley of death across preclinical and clinical trials. It is hoped that such difficulties will be overcome in the near future.

Key words: Chagas disease - chronic chagasic cardiomyopathy - preclinical tests - benznidazole - pentoxifylline - multi-therapy

**Chronic chagasic cardiomyopathy (CCC): a hallmark of Chagas disease**

Inflammation-related tissue injury associated with low-grade parasite persistence, progressive fibrosis, cardiac dysfunction, potentially evolving to heart failure, and systemic inflammatory profile are hallmarks of chronic Chagas’ heart disease. This is the main clinical manifestation of Chagas disease (CD), a neglected tropical disease caused by the protozoan parasite *Trypanosoma cruzi*, discovered more than hundred and twenty years ago. CD afflicts 7-8 million people, mostly in endemic areas of Latin America, and human migration contributes to globalisation of this health problem.(1,3) Prophylactic and therapeutic vaccines are not available.(2) Currently, most chronically CD patients with access to clinical follow-up are only prescribed with signs- and symptoms-based treatments.(1,3)

After *T. cruzi* infection, acute phase lasts four to eight weeks. In this phase, the parasite is detected in circulating blood and tissues, triggering an inflammation-related immune response.(4) The immune response generated in the acute phase, and still present in the chronic phase, with the production of antibodies and activation of effector T-cells, may control the intense parasitism and parasitaemia, which becomes low and intermittent, however it fails to eliminate the parasite.(5) The molecular mechanisms contributing to the persistence of *T. cruzi* parasite amastigote forms in tissues and, particularly, inside certain cells as cardiomyocytes, in the chronic phase of CD need to be identified. In the acute and chronic phases, parasite antigens and extracellular vesicles containing *T. cruzi* molecules and cargos of parasite-host cell interactions are detected in plasma and tissues. In this way, low-grade tissue parasitism may contribute to continuous stimulation of tissue cells and, particularly, of cells of the immune system.(5) In the chronic phase, high titers of antibodies (IgG) are biomarker of diagnosis and disclose persistence of the infection, being seroconversion a potent, but time-consuming, cure criterion.(5) Thus, therapies targeting parasite are a demand to add advantageous to immune-mediated parasite control and impact disease progression. Effectiveness of the offered etiological treatments targeting *T. cruzi*, benznidazole (Bz) and nifurtimox, is considered high in the acute phase of infection (60-80%), however most of the patients miss diagnosis and treatment. Pitifully, efficacy of these medications drops in the chronic phase of the infection.
The presence of mononuclear inflammatory cells infiltrating the heart tissue and the high rate of mortality are distinct features of CCC compared to other chronic myocardopathies. Also, a systemic inflammatory profile, resembling a “cytokine storm” with increased serum concentrations of inflammatory (IL-6, TNF, IL-17, IFNγ) and regulatory (IL-4, IL-10, TGFβ) cytokines, and inflammatory mediators as nitric oxide (NO), is associated with the severity of Chagas’ heart disease but absent in non-cardiopathic and indeterminate form CD patients. Thus, in cardiopathic CD patients, low-grade parasite persistence coexists with inflammation-related tissue changes and a systemic inflammatory profile. Some years ago, we initiated our studies believing that the comprehension of host-parasite interplay contributing to CCC pathogenesis could unveil targets for rational trait-based modulatory therapies. Here, along with our network of collaborators and other groups’ work on CCC, I recapitulate and critically review a collection of data obtained, modelling proposals of multi-therapeutic strategies aiming at improving CCC prognosis.

**Pathogenic mechanisms and modulatory preclinical strategy tests to CCC**

Preclinical models of CD, combining mouse lineages and *T. cruzi* strains, emerge as tools to replicate parasitological, immunological and clinical features of CCC. The use of these models may allow (i) studies on molecular mechanisms underlying pathogenesis, (ii) unbiased screen studies, and (iii) hypothesis-based tests targeting potential pathogenic traits, thus contributing to identify therapeutic targets to be further tested in clinical trials aiming at improving CCC prognosis. Our results support that, according to the experimental model used, the initial host response to invader may define the severity of the chronic phase of the infection, therefore, opening an opportunity to test strategies to modify the clinical outcome, hampering progression or, preferentially, reversing CCC features. Different mouse lineages (C57BL/6 and C3H/He) infected with the same *T. cruzi* strain (Colombian, DTU TcI) show degrees of CCC severity (mild and severe), characterised by the intensity of electrocardiographic (arrhythmias, prolongation of PR and QTc intervals and QRS complex) and echocardiographic changes. In these models, the intensity of parasitaemia and heart parasitism in the acute phase of the infection was associated with the degree of CCC severity, manifested by the intensity of parasitism, inflammation, loss of the gap junction protein connexin-43 (Cx43) and progressive fibrosis in the heart tissue. In addition, CCC severity was directly related to CK-MB activity serum levels, a biomarker of cardiomyocyte injury, and systemic inflammatory profile, with increased serum levels of tumor necrosis factor (TNF) and nitric oxide (NO) thus replicating key aspects of chronic Chagas’ heart disease.

In a proof-of-concept study to test TNF participation in CD pathogenesis, acutely *T. cruzi*-infected C3H/He mice were treated with the anti-TNF antibody infliximab. Survival was paralleled by reduced heart inflammation and tissue damage, without interference in parasite control, placing TNF as a key cytokine in the pathogenesis of *T. cruzi*-elicited cardiac disease. Moreover, all the results obtained after administration of the anti-TNF blocking antibody (infliximab) to chronically *T. cruzi*-infected C57BL/6 mice showing clinical signs of CCC support that TNF contributes to tissue damage, Cx43 loss, and electrical changes as arrhythmias, second-degree atrioventricular blockage (AVB-2), and prolongation of the PR and QTc intervals and QRS complex. In addition, TNF blockage reduced the frequencies of IL-17+CD4+ cells and TNF receptor 1 (TNFR1)-bearing CD8+ T cells, while increased the frequency of IL-10+ macrophages in spleen. Particularly, TNF blockage strategy placed TNF signaling as an upstream regulator of the balance of systemic proinflammatory (IFNγ, TNF and IL-17) and regulatory (IL-10) cytokines in the chronic infection. Crucially, TNF blockage downregulated TNF mRNA expression in the cardiac tissue and reduced infiltration by cytotoxic CD8+ T cells. In another study, administration of pentoxifylline (PTX), a phosphodiesterase inhibitor with hemorheological properties, to chronically *T. cruzi*-infected mice with signs of CCC reduced the frequency of TNFR1+CD8+ T cells. Moreover, PTX therapy restored the infection-induced TCR downregulation and improved parasite-specific CD8+ mediated immune response. The repositioning of the abnormal CD8+ T cell response was associated with reversion of CCC traits, as electrical and echocardiographic abnormalities. Altogether, these data support a pivotal role for TNF/TNFR1 signaling in myocarditis formation, tissue injury, as well as conductive and functional changes in CCC.
In the acute phase, TNF and IFNγ are essential for chemokine-driven cell migration and cardiac tissue colonisation by inflammatory cells associated with parasite control. TNF and IFNγ also induce the production of reactive oxygen species (ROS) and other effector mechanisms crucial for control of parasite dissemination. However, in an apparent paradox, ROS fuels T. cruzi growth and is involved in functional impairment of the heart. More, ROS and oxidative stress induce deleterious effects on the respiratory chain of cardiac cell mitochondria in CD patients and T. cruzi-infected mice, resembling features of mitochondriopathies. In this context, reduction in the levels of the antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase (SOD) were associated with the worsening of Chagas’ heart disease.

In the chronic infection, the proinflammatory effector mechanisms (TNF, IFNγ, ROS) that contribute to parasite control may also cause tissue injury and clinical changes. Although regulatory effector mechanisms such as regulatory T cells, IL-10 and TGFβ may contribute to disease tolerance, lowering the microbial activity of macrophages in tissue, they also upregulate the production of arginase-induced putrescine, which fuels parasite growth. TGFβ also plays a direct role in parasite escape of the immune response, promoting cardiac cell invasion and parasite growth. Moreover, increased TGFβ plasma levels in the early chronic phase of CD were proposed as predictor of CCC progression and risk of death. In this context, CCC model in Colombian-infected C57BL/6 mice showed elevated TGFβ serum levels and TGFβ expression in heart tissue associated with increased expression and activity of the metalloproteinase MMP9, tissue remodeling and fibrosis. Crucially, blockade of TGFβ signaling using GW788388, a selective inhibitor of TβR1/ALK5, showed that this cytokine contributes to Cx43 loss and plays a fibrogenic role, worsening conduction and cardiac dysfunction. Altogether, these data support the complexity of cytokine contribution to CCC pathogenesis.

In CCC patients, myocarditis is composed of mononuclear cells, mainly cytotoxic CD8+ (granzyme A+ cells), and CD4+ T cells and macrophages. In addition, elevated serum levels of CC-chemokine ligands and CC-chemokine receptors in T-cells and macrophages are related with severity of Chagas’ heart disease. Thus, a role for CC-chemokines in the coordination of migration of these cells towards the cardiac tissue has been proposed. In the acute and chronic infection of C3H/He and C57BL/6 mice with the Colombian strain, CC-chemokine concentrations in the heart tissue are related with the intensity of inflammation. Studies using mouse lineages deficient in CC-chemokine ligand (CCL3) or receptor (CCR5) and selective CCR1/CCR5 antagonist revealed that CCL3, CCL4 and CCL5 ligands, acting via the CCR1/CCR5 receptors, control the migration of T cells and macrophages towards the cardiac tissue, cause cardiomyocyte lesion and conduction and functional abnormalities. Moreover, CCL3 was posed as a hub in CCC pathogenesis, regulating the intensity of TNF- and IFNγ-enriched inflammatory milieu, the degree of cardiomyocyte injury, prolonged QTc interval and cardiac dysfunction. Hence, these findings reinforce a role for TNF and IFNγ in T. cruzi-triggered cardiomyocyte damage, and conduction and functional changes, pivotal features of CCC.

The molecular mechanisms that underpin the pathogenesis of CCC to be unravelled are urgent need. In the cardiac tissue of patients with CD and in CCC model using Colombian-infected C57BL/6 mice, upregulation and downmodulation of the expression of certain microRNAs (miRNAs), molecules that specifically control mRNA translation, have been described. In acutely Colombian-infected C57BL/6 mice, predictive analysis supports the correlation of changes in miRNAs (miR-21, miR-145-5p and miR-146b-5p) in the cardiac tissue with parasitaemia levels and prolonged QTc interval, and with molecules essential for cardiac activity, as metabolite and ion channels (as GJA5, KCNAl). Further, target gene network analysis supports the association of pivotal miRNAs with the expression of relevant molecules, biological pathways, signaling signatures and mitochondrial dysfunction, placing IFNγ, TNF, NFkB as upstream regulators of miRNAs and miRNAs. Crucially, these findings were recently supported by analysis of the heart of CCC patients. Also, miR-155 miRNA has been associated with T. cruzi infection control and serum levels of the inflammatory cytokines IFNγ and TNF. Moreover, a recent study showed that co-exposure of human cardiomyocytes to IFNγ and TNF induces nitro-oxidative stress and mitochondrial dysfunction, reinforcing the direct effect of these proinflammatory cytokines in cardiac cell injury.

Increased TNF and soluble TFNRI (sTNFR1) serum levels, biomarkers of systemic inflammatory diseases, are detected in chronic CD patients regardless of clinical forms. Severity of CCC is correlated with high serum levels of proinflammatory (IL-6, IL-17, IFNγ, TNF) and regulatory (IL-4, IL-10, TGFβ) cytokines, chemokines (CCL2, CCL3, CCL5), and the inflammatory mediators NO. Although most evidence lacks causal correlation, these data suggest that CCC is associated with a systemic inflammatory profile. Regardless the academic requirements for causa-effect relation in CCC patients, in experimental models subjected to therapeutic interventions with an adenovirus-based vaccine, anti-TNF, PTX, TGFβ signaling blocker or the trypanocidal drug Bz the results support that lowering the systemic inflammatory cytokine levels plays beneficial role in CCC progression. Reinforcing this idea, in a study performed in an indeterminate model of CD, low serum cytokine levels, like those of uninfected controls, parallel low-grade cardiac parasitism and inflammation in the absence of clinical signs of heart disease.

Here, we bring a cartoon summarising data obtained in CD patients and preclinical studies and a proposal to Chagas’ heart disease pathogenesis. In the acute phase of infection, low inflammatory cytokines and NO levels are crucial for parasite control. However, as infection progresses to chronic phase, low-grade parasitism persists, and TNF, sTNFR1 and NO serum levels are associated with disease severity. Tissue infiltration by inflammatory cells is sustained and this long-lasting scenario may contribute to tissue damage with CC-chemokines / inflammation, TNF and IFNγ-enriched milieu, miRNA/
mRNA dysregulation, ion channels changes, ROS increase, oxidative stress, mitochondrial dysfunction, increased MMP9 activity, hypertrophy, tissue remodeling and fibrosis, thus contributing to conduction and functional changes (Fig. 1). Altogether, the above discussed studies highlight the pivotal role of signaling pathways triggered by proinflammatory cytokines (particularly, IFNγ and TNF) in heart tissue injury, as well as conduction and functional activities, opening perspectives for the comprehension of the molecular mechanisms underlying the pathogenesis of CCC and the proposal of trait-based immunomodulatory strategies.

Multi-therapeutic strategy targeting parasite and inflammation-related alterations impacts CCC progression

A bunch of evidence support multifactorial contributions to CCC as (i) parasite persistence, (ii) inflammation-related tissue damage, and (iii) systemic inflammatory profile. Keeping this in mind, we carried out a hypothesis-based study testing effectiveness of a reduced dose of Bz (25 mg/Kg/day, 1/4 of the usual dose, 30 consecutive days), aiming at diminishing parasite load, combined with PTX, to use immunoregulatory properties to interfere with traits associated with CCC. Our idea was challenged in chronically Colombian-infected C57BL/6 mice showing clinical signs of CCC. Several analyses were carried out, as shown in our previous publications. Briefly, low dose of Bz was effective in heart parasite control with no significant impact on electrical abnormalities, at the end of treatment. However, 30 days after treatment cessation conduction changes were improved, suggesting that time is required to recover tissue damage. Indeed, in a long-term follow-up, Bz therapy was associated with decreased incidence of CD progression form indeterminate to cardiac form and cardiac events. In our study, PTX did not interfere with Bz-induced parasite control but presented partial beneficial effects on conduction alterations. Moreover, after Bz+PTX therapy conduction changes were improved. Particularly, the QTc prolongation, a biomarker associated with cytokine-related inflamed heart tissue, seen in vehicle-treated (Veh) infected mice was restored, alike uninfected controls, in Bz+PTX-treated mice (Fig. 2A). Importantly, the three therapeutic schemes reduced heart fibrosis. Moreover, Bz therapy reduced the levels of TNF mRNA expression in heart tissue and sTNFR1 serum levels. Therapy with suboptimal dose of Bz mitigated Th1-driven molecular pathways detected in Veh-treated group, while combined Bz+PTX modulated cell death and survival pathways, which may improve CCC progression. Crucially, Bz and Bz+PTX strategies downregulated IFNγ, an upstream regulator of miRNA and mRNA expression in the heart tissue. Here, a new glance was lanced at these data focusing on a group of molecules that may contribute to inflammation-related alterations playing a role in major biological processes as cell migration (CCL3, CCL5, CXCL10, CXCL11, CXCR3), myocarditis formation (CD3ε, CD8α, CD4, CD19), inflammation (IFNγ, IL-10, IL-12a, IL-15, IL2R, IL-1Ra, IL-6, IL-7), and cytotoxic activity of T-cells (CTL; granzyme, perforin). In comparison with uninfected controls, Veh-treated infected mice present a global increase in the expression of these molecules in the heart tissue, reduced by suboptimal dose of Bz and, mainly, by the combined Bz+PTX therapy (Fig. 2B). Therefore, rational treatment with suboptimal dose of the trypanocidal drug Bz reduces parasitism and combined with the immunoregulator PTX shows modulatory effects on a group of relevant upregulated genes in experimental CCC. This new scenario may reduce the continuous cell migration towards heart tissue and inflammation-related changes, which may allow tissue healing and improve disease tolerance. Thus, multi-therapeutic strategy targeting parasite and inflammation-related alterations may add beneficial effects to improve CCC prognosis and, even, reverse chronic cardiac alterations.

Final remarks

Besides our results discussed above, Fig. 3 summarises potential pharmacological and non-pharmacological candidate strategies to confront the complexity of the molecular mechanisms underpinning the pathogenesis of Chagas’ heart disease and improve prognosis, regarding the three major factors that may sustain CCC: (i) parasite persistence, (ii) intrinsic cardiac alterations, and (iii) immunological unbalance in heart and systemic inflammatory profile. To control parasite persistence, patients may benefit of protocols lowering doses of Bz or using short-term administration schemes, to preclude side effects. Certainly, novel drugs targeting parasite biological circuits may offer new opportunities to eliminate infection and even present the possibility of a drug cocktail targeting parasite for CD therapy. Consideration of the comprehension of the molecular mechanisms underlying the pathogenesis of CCC and the proposal of trait-based immunomodulatory strategies.

**Fig. 1:** cytokines and inflammatory mediators may take part in parasite control but may also play a role in the pathogenesis of Chagas’ heart disease, fueling inflammation-related tissue damage. In the acute phase of the infection, antibodies (Ab) and low levels of cytokines (as TNF, IFNγ) and inflammatory mediator (as NO) are crucial for parasite control. As infection progresses to chronic phase, TNF, sTNFR1 and NO serum levels are associated with chronic chagasic cardiomyopathy (CC) severity. Parasite persistence and this long-lasting systemic inflammatory profile scenario may contribute to inflammation-related heart tissue damage with increased expression of CC-chemokines / inflammation, TNF-and IFNγ-enriched milieu, miRNA/mRNA dysregulation, changes of ion channels expression, reactive oxygen species (ROS) increase, oxidative stress, mitochondrial dysfunction, increased MMP9 activity, hypertrophy, tissue remodeling and fibrosis, thus contributing to conduction and functional changes.
erring intrinsic cardiac alteration, Chagas’ heart disease patients may benefit of pharmacological therapies currently used to treat other cardiac conditions. Some sign- and symptom-based pharmacological therapies are indicated to treat CD patients, as the antiarrhythmic agent amiodarone and drugs to interfere with the dysfunction-al neurohormone circuits, as renin-angiotensin-aldosterone system (RAAS), inhibitors of angiotensin converting enzyme - ACEi - and angiotensin receptor blockers - ARB; antioxidant agents or nutritional approaches using resveratrol and selenium, and (iii) immunological unbalance in heart and systemic inflammatory profile (target by immunoregulators as PTX and TGF signaling blocker, therapeutic vaccines, immunomodulatory properties of Low dose of Bz). Non-pharmacological strategies as physical exercises may also contribute to improve CCC prognosis.

![Fig. 2: multi-therapeutic strategy targeting parasite and inflammation-related tissue changes impacted experimental chronic chagasic cardiomyopathy (CCC). Colombian-infected C57BL/6 mice showing clinical signs of CCC received vehicle (Veh), suboptimal dose of the trypanocidal drug benznidazole (Bz) or Bz plus the immunomodulator pentoxifylline (Bz+PTX). (A) The prolonged QTc, seen in vehicle-treated (Veh) infected mice was not impacted by Bz therapy, but restored, alike uninfected controls, after Bz+PTX therapy. (B) Data on gene expression in the heart tissue were reanalysed, focusing on the expression of molecules associated with cell migration (CCL3, CCL5, CXCL10, CXCL11, CXCR3), myocarditis (CD3e, CD8a, CD4, CD19), inflammation (IFNγ, IL-10, IL-12a, IL-15, IL2R, IL-1Ra, IL-6, IL-7), and cytotoxic activity of T-cells (CTL; granzyme, perforin). Compared with uninfected controls, in Veh-treated infected mice most of these genes were upregulated. Therapy with Bz and, crucially, Bz+PTX, mitigated the expression of these genes.

![Fig. 3: pharmacological and non-pharmacological potential candidates to compose multi-therapeutic strategies to confront the complexity of Chagas’ heart disease. Three major factors may sustain chronic chagasic cardiomyopathy (CCC): (i) parasite persistence (target by Low doses of Bz; New drugs), (ii) intrinsic cardiac alterations (target by the antiarrhythmic agent amiodarone; inhibitors of angiotensin converting enzyme - ACEi - and angiotensin receptor blockers - ARB; antioxidant agents or nutritional approaches using resveratrol and selenium), and (iii) immunological unbalance in heart and systemic inflammatory profile (target by immunoregulators as PTX and TGF signaling blocker, therapeutic vaccines, immunomodulatory properties of Low dose of Bz). Non-pharmacological strategies as physical exercises may also contribute to improve CCC prognosis.](image-url)
CD patients to screening and clinical follow-up; (ii) the deceptive pursuit for the silver bullet for the etiological treatment of CD patients; (iii) the lack of recognition that CD is an multi-factorial disease, with a parasite-triggered systemic inflammatory profile and other pivotal biological pathways; (iv) the lack of consensual biomarkers to follow-up effects of therapeutic protocols; and (v) the valley of death separating preclinical and clinical trials to treat neglected tropical diseases, as CD. Among the new perspectives in a post-pandemic world, all the recent advances in the comprehension of the host-invader interplay, drug and vaccine development, may allow more receptive minds to test vaccines and new therapeutic strategies accessible to millions of people afflicted by neglected diseases, as Chagas disease.

ACKNOWLEDGEMENTS

To the MSc and PhD students of the Laboratory of Biology of the Interactions, IOC/Fiocruz, and all collaborators that contributed to the work discussed here. In special, I would like to thank Dr Isabela Resende Pereira, Dr. Glau- cia Vilar-Pereira and Dr Priscila Farani for our discussions, mostly during their PhD studies.

REFERENCES

1. Dias JC, Ramos Jr AN, Gontijo ED, Luquetti A, Shikanai-Yasuda MA, Coura JR, et. [Brazilian Consensus on Chagas Disease, 2015]. Epidemiol Serv Saude. 2016; 25(sup): 7-86.
2. Camargo EP, Gazzinelli RT, Morel CM, Precioso AR. Why do we still have not a vaccine against Chagas disease? Mem Inst Oswaldo Cruz. 2021; 116: e200314.
3. Saraiva RM, Meymandi S. Management of chronic chagasic cardiomyopathy in endemic and non-endemic countries: challenges and limitations. In Delgado MJP, Gascón J, editors. Chagas disease - a neglected tropical disease. Springer; 2020. p. 145.
4. Acevedo GR, Girard MC, Gómez KA. The unsolved jigsaw puzzle of the immune response in Chagas disease. Front Immunol. 2018; 9: 1929.
5. Dantas-Pereira L, Menna-Barreto R, Lannes-Vieira J. Extracellular vesicles: potential role in remote signaling and inflammation in Trypanosoma cruzi-triggered disease. Front Cell Dev Biol. 2021; 9: 798054.
6. Urbina J. Etiologic treatment of Chagas disease: old drugs, new insights, challenges, and perspectives. In Delgado MJP, Gascón J, editors. Chagas disease - a neglected tropical disease. Springer; 2020. p. 123.
7. Rassi Jr A, Marin-Neto JA, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of acetylcysteine treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz. 2017; 112(3): 224-35.
8. Bocchi EA, Bestetti RB, Scavaccia MI, Cunha Neto E, Issa VS. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol. 2017; 70(12): 1510-24.
9. Pérez-Fuentes R, Guégan JF, Barnabé C, López-Colombo A, Salgado-Rosas H, Torres-Rasgado E, et al. Severity of chronic Chagas disease is associated with cytokine/antioxidant imbalance in chronically infected individuals. Int J Parasitol. 2003; 33(3): 293-9.
10. Pérez AR, Silva-Barbosa SD, Berbert LR, Revelli S, Beloscar J, Savino W, et al. O Immunoneuroendocrine alterations in patients with progressive forms of chronic Chagas disease. J Neuroimmunol. 2011; 235(1-2): 84-90.
11. Neves EGA, Koh CC, Padilha da Silva JL, Passos LS, Villani FNA, dos Santos JSC, et al. Systemic cytokines, chemokines and growth factors reveal specific and shared immunological characteristics in infectious cardiomyopathies. Cytokine. 2021; 148: 155711.
12. Pereira IR, Vilar-Pereira G, da Silva AA, Lannes-Vieira J. Severity of chronic experimental Chagas’ heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease. Mem Inst Oswaldo Cruz. 2014; 109(3): 289-98.
13. Dalry A, Pereira IR, Pereira-Junior PP, Ramos IP, Vilar-Pereira G, Silvaes RR, et al. Levels of circulating anti-muscarinic and anti-adrenergic antibodies and their effect on cardiac arrhythmias and dysautonomia in murine models of Chagas disease. Parasitol. 2014; 141(13): 1769-78.
14. Silverio JC, Pereira IR, Cipitelli MC, Vinagre NF, Rodrigues MM, Gazzinelli RT, et al. CD8+ T-cells expressing interferon gamma or perforin play antagonist roles in heart injury in experimental Trypanosoma cruzi-elicted cardiomyopathy. PLoS Pathog. 2012; 8(4): e1002645.
15. Pereira IR, Vilar-Pereira G, Marques V, da Silva AA, Caetano B, Moreira OC, et al. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog. 2015; 11(1): e1004594.
16. Kroll-Palhares K, Silverío JC, da Silva AA, Michelowski Y, Marino AP, Silva NM, et al. TNF/TNFR1 signaling up-regulates CCR5 expression by CD8+ T lymphocytes and promotes heart tissue damage during Trypanosoma cruzi infection: beneficial effects of TNF-alpha blockade. Mem Inst Oswaldo Cruz. 2008; 103(4): 375-85.
17. Pereira IR, Vilar-Pereira G, Silva AA, Moreira OC, Britto C, Sarmento ED, et al. Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas’ heart disease. Mediators Inflamm. 2014; 2014: 798078.
18. Pereira IR, Vilar-Pereira G, Moreira OC, Ramos IP, Gibaldi D, Britto C, et al. Pentoxifylline reverses chronic experimental Chagas cardiomyopathy in association with repositioning of abnormal CDW1-negative T-cell response. PLoS Negl Trop Dis. 2015; 9(3): e0003659.
19. Teixeira MM, Gazzinelli RT, Silva JS. Chemokines inflammation and Trypanosoma cruzi infection. Trends Parasitol. 2002; 18(6): 262-5.
20. Paiva CN, Medei E, Bozza MT. ROS and Trypanosoma cruzi: fuel to infection, poison to the heart. PLoS Pathog. 2018; 14(4): e1006928.
21. Wen JJ, Yacheli PC, Sembaj A, Manzur RE, Garg NJ. Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients. Free Radic Biol Med. 2006; 41(2): 270-6.
22. Wen JJ, Garg NJ. Manganese superoxide dismutase deficiency exacerbates the mitochondrial ROS production and oxidative damage in Chagas disease. PLoS Negl Trop Dis. 2018; 12(7): e0006687.
23. Chevillard C, Nunes JPS, Frade AF, Almeida RR, Pandey RP, Nascimento MS, et al. Disease tolerance and pathogen resistance genes may underlie Trypanosoma cruzi persistence and differential progression to Chagas disease cardiomyopathy. Front Immunol. 2018; 9: 2791.
24. Freire-de-Lima CG, Nascimento DO, Soares MB, Bozza PT, Castro-Faria-Neto HC, de Mello FG, et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature. 2000; 403(6766): 199-203.
25. Waghabi MC, Ferreirra RR, Abreu RS, Degrave W, de Souza EM, Bailly S, et al. Transforming growth factor-β as a therapeutic target for the cardiac damage of Chagas disease. Mem Inst Oswaldo Cruz. 2022; 116: e210395.
induces mitochondrial dysfunction and nitro-oxidative stress: implications for the pathogenesis of chronic Chagas disease cardiomyopathy. Front Immunol. 2021; 12: 755862.

26. Saraiva RM, Waghabi MC, Vilela MF, Madeira FS, Sperandio da Silva GM, Xavier SS, et al. Predictive value of transforming growth factor-β in Chagas disease: towards a biomarker surrogate of clinical outcome. Trans R Soc Trop Med Hyg. 2013; 107(8): 518-25.

27. Ferreira RR, Abreu RDS, Vilar-Pereira G, Degrave W, Meusser-Batista M, Ferreira NVC, et al. TGF-β1 inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas’ heart disease. PLoS Negl Trop Dis. 2019; 13(7): e0007602.

28. Reis DD, Jones EM, Tostes Jr S, Lopes ER, Gazzinelli G, Colley DG, et al. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A”, CD8+ lymphocytes. Am J Trop Med Hyg. 1993; 48(5): 637-44.

29. Medeiros GA, Silvério JC, Marino AP, Roffê E, Vieira V, Kroll-Palharc K, et al. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect. 2009; 11(2): 264-73.

30. Gibaldi D, Vilar-Pereira G, Pereira IR, Silva AA, Barrios LC, Ramos IP, et al. CCL3/macrophage inflammatory protein-1α is dually involved in parasite persistence and induction of a TNF-α and IFNγ-enriched inflammatory milieu in Trypanosoma cruzi-induced chronic cardiomyopathy. Front Immunol. 2020; 11: 306.

31. Marino AP, da Silva A, dos Santos P, Pinto LM, Gazzinelli RT, Teixeira MM, et al. Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicted myocarditis. Circulation. 2004; 110(11): 1443-9.

32. Batista AM, Alvarado-Arnez LE, Alves SM, Melo G, Pereira IR, Ruivo LAS, et al. Genetic polymorphism of CCL5 is associated with protection in Chagas’ heart disease: antagonistic participation of CCR1 and CCR5+ cells in chronic chagasic cardiomyopathy. Front Immunol. 2018; 9: 615.

33. Ferreira LR, Frade AF, Santos RH, Teixeira PC, Baron MA, Navarro IC, et al. MicroRNAs miR-1, miR-133a, miR-133b, miR-208a and miR-208b are dysregulated in chronic chagasic disease cardiomyopathy. Int J Cardiol. 2014; 175(3): 409-17.

34. Laugier L, Ferreira LRP, Ferreira FM, Cabantous S, Frade AF, Nunes JP, et al. MicroRNAs may play a major role in the control of gene expression in key pathological processes in Chagas disease cardiomyopathy. PLoS Negl Trop Dis. 2020; 14(12): e0008889.

35. Navarro IC, Ferreira FM, Nakaya HI, Baron MA, Vilar-Pereira G, Pereira IR, et al. MicroRNA transcriptome profiling in heart of Trypanosoma cruzi-infected mice: parasitological and cardiological outcomes. PLoS Negl Trop Dis. 2015; 9(6): e0003828.

36. Ferreira LRP, Ferreira FM, Laugier L, Cabantous S, Navarro IC, Cándido DS, et al. Integration of miRNA and gene expression profiles suggest a role for miRNAs in the pathobiological processes of acute Trypanosoma cruzi infection. Sci Rep. 2017; 7(1): 17990.

37. Jha BK, Varikutti S, Seidler GR, Volpedo G, Satoškas AR, McGwire BS. MicroRNA-155 deficiency exacerbates Trypanosoma cruzi infection. Infect Immun. 2020; 88(7): e00948-19.

38. Nunes JPS, Andrieux P, Brochet P, Almeida RR, Kitanô E, Honda AK, et al. Co-exposure of cardiomyocytes to IFN-γ and TNF-α induces mitochondrial dysfunction and nitro-oxidative stress: implications for the pathogenesis of chronic Chagas disease cardiomyopathy. Front Immunol. 2021; 12: 755862.

39. Torres DJL, Arruda TR, Barros MDS, Gonçalves JP, Soares AK, Oliveira KKDS, et al. Is a negative correlation between sTNFR1 and TNF in patients with chronic Chagas disease the key to clinical progression? Immunobiology. 2021; 227(1): 152166.

40. de Araújo FF, Torres KCL, Peixoto SV, Ribeiro ALP, Mambrini JVM, Rezende VB, et al. CXCL9 and CXCL10 display an age-dependent profile in Chagas patients: a cohort study of aging in Bambuí, Brazil. Infect Dis Poverty. 2020; 9(1): 51.

41. Vilar-Pereira G, Pereira IR, Ruivo LAS, Moreira OC, da Silva AA, Britto C, et al. Combination chemotherapy with suboptimal doses of Benznidazole and Pentoxifylline sustains partial reversal of experimental Chagas’ heart disease. Antimicrob Agents Chemother. 2016; 60(7): 4297-309.

42. Pedro-Rezende Y, Barbosa JMC, Bombaça ACS, Dantas-Pereira L, Gibaldi D, Vilar-Pereira G, et al. Physical exercise promotes a reduction in cardiac fibrosis in the chronic indeterminate form of experimental Chagas disease. Front Immunol. 2021; 12: 712034.

43. Farani PSG, Begum K, Vilar-Pereira G, Pereira IR, Almeida IC, Roy S, et al. Treatment with suboptimal dose of Benznidazole mitigates immune response molecular pathways in mice with chronic Chagas cardiomyopathy. Front Cell Infect Microbiol. 2021; 11: 692655.

44. Hasslocher-Moreno AM, Saraiva RM, Sangenis LHC, Xavier SS, de Sousa AS, Costa AR, et al. Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: a long-term follow up study. E ClinicalMedicine. 2020; 51: 100694.

45. Lazzerini PE, Capecci PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med. 2015; 2: 26.

46. Soeiro MNC. Perspectives for a new drug candidate for Chagas disease therapy. Mem Inst Oswaldo Cruz. 2022; 117: e220004.

47. Vilar-Pereira G, Carneiro VC, Mata-Santos H, Vicentino AR, Ramos IP, Giarola NL, et al. Resveratrol reverses functional Chagas heart disease in mice. PLoS Pathog. 2016; 12(10): e1005947.

48. Holanda MT, Mediano MFF, Hasslocher-Moreno AM, Gonzaga BMS, Carvalho ACC, Ferreira RR, et al. Effects of selenium treatment on cardiac function in Chagas heart disease: results from the STCC randomized trial. EClinicalMedicine. 2021; 40: 101105.

49. Araujo-Jorge TC, Ferreira RR. Translational research in Chagas disease: perspectives in nutritional therapy emerging from seleni supplementation studies as a complementary treatment. Mem Inst Oswaldo Cruz. 2022; 117: e220001.

50. Shaw SM, Shah MK, Williams SG, Fildes JE. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail. 2009; 11(2): 113-8.

51. Ronco MT, Manarin R, Francês D, Serra E, Revelli S, Carvalho ACC, Ferreira RR, et al. Effects of selenium treatment on cardiac function in Chagas heart disease: results from the STCC randomized trial. EClinicalMedicine. 2021; 40: 101105.

52. Lima MM, Rocha MO, Nunes MC, Sousa L, Costa HS, Alencar Bambuí, Brazil. Infect Dis Poverty. 2020; 9(1): 51.